All Latest News
-
Adare Pharmaceuticals and NLS Pharmaceutics collaborate to develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy
Press Release ArchivesLawrenceville, NJ & Switzerland - January 13, 2020 Adare Pharmaceuticals, Inc. (Adare) and NLS Pharmaceutics Ltd. (NLS) announced today a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy... Learn More
-
Adare acquires Egalet’s proprietary “Parvulet®” technology platform
Press Release ArchivesPrinceton, NJ & Wayne, PA - April 15, 2019 Adare Pharmaceuticals, Inc. today announced that it has entered into an agreement with Egalet Corporation (OTCQX: ZCOR), to acquire global rights of the “ParvuletTM” technology platform... Learn More
-
Primary End-Point achieved in Phase IIb Study (FLUTE™) for APT-1011
Press Release ArchivesPrinceton, New Jersey - March 12, 2019 Adare Pharmaceuticals (Adare) today announced positive results from its Phase IIb study (FLUTE™) for one of its rare disease investigational products, APT-1011 (AdvaTab® Fluticasone) for... Learn More
-
Lannett and Adare Enter Into Distribution Agreement
Press Release ArchivesPhiladelphia, PA & Princeton, New Jersey - October 22, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of... Learn More
-
Adare Licenses Cyclobenzaprine Hydrochloride in Portugal
Press Release ArchivesPrinceton, New Jersey - October 8, 2018 Adare Pharmaceutical Technologies, the specialty CDMO business unit of Adare Pharmaceuticals, has completed a licensing and supply agreement with Bene Farmacêutica (Bene) for cyclobenzaprine... Learn More
-
Adare Pharmaceuticals announces changes to Executive Leadership Team
Press Release ArchivesPrinceton, New Jersey - May 8, 2018 Adare Pharmaceuticals, Inc., today announced changes to its Leadership Team to support the next phase of its growth strategy. Since its creation in 2015, the Company has been committed to becoming a... Learn More
-
John Fraher, CEO of Adare Pharmaceuticals Named EY Entrepreneur of the Year® 2017 Award Winner in New Jersey
Press Release ArchivesLAWRENCEVILLE, N.J.--(BUSINESS WIRE)-- John Fraher, CEO of Adare Pharmaceuticals, a private global pharmaceutical company, has been named Ernst & Young’s Entrepreneur of the Year in the life sciences category in New Jersey. Fraher... Learn More
-
Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening
Press Release ArchivesLawrenceville, New Jersey - September 28, 2016 Adare Pharmaceuticals, a private global specialty pharmaceutical company, celebrated the official opening of its Corporate Headquarters located at 1200 Lenox Drive in Lawrenceville, New... Learn More
-
Adare Pharmaceuticals Company Spotlight Presentation at BIO International 2016 Convention
Press Release ArchivesSan Francisco, CA - June 6, 2016 Adare Pharmaceuticals, a global specialty pharmaceutical company, will present its company overview on Tuesday, June 7, at 1:45 PM, in Room 1, at the 2016 BIO International Convention. Hosted by the... Learn More
-
Adare Pharmaceuticals Partners with Cincinnati Children’s on Innovation Fund
Press Release ArchivesPRINCETON, N.J. & CINCINNATI, OH--(BUSINESS WIRE)-- Adare Pharmaceuticals, Inc. and the Cincinnati Children’s Hospital Medical Center today announced that they are partnering together on an Innovation Fund, which will focus on... Learn More
